Advanced SearchSearch Tips
Efficacy of Prophylactic Entecavir for Hepatitis B Virus-Related Hepatocellular Carcinoma Receiving Transcatheter Arterial Chemoembolization
facebook(new window)  Pirnt(new window) E-mail(new window) Excel Download
 Title & Authors
Efficacy of Prophylactic Entecavir for Hepatitis B Virus-Related Hepatocellular Carcinoma Receiving Transcatheter Arterial Chemoembolization
Li, Xing; Zhong, Xiang; Chen, Zhan-Hong; Wang, Tian-Tian; Ma, Xiao-Kun; Xing, Yan-Fang; Wu, Dong-Hao; Dong, Min; Chen, Jie; Ruan, Dan-Yun; Lin, Ze-Xiao; Wen, Jing-Yun; Wei, Li; Wu, Xiang-Yuan; Lin, Qu;
  PDF(new window)
Background and Aims: Hepatitis B virus (HBV) reactivation was reported to be induced by transcatheter arterial chemoembolization (TACE) in HBV-related hepatocellular carcinonma (HCC) patients with a high incidence. The effective strategy to reduce hepatitis flares due to HBV reactivation in this specific group of patients was limited to lamivudine. This retrospective study was aimed to investigate the efficacy of prophylactic entecavir in HCC patients receiving TACE. Methods: A consecutive series of 191 HBV-related HCC patients receiving TACE were analyzed including 44 patients received prophylactic entecavir. Virologic events, defined as an increase in serum HBV DNA level to more than 1 log10 copies/ml higher than nadir the level, and hepatitis flares due to HBV reactivation were the main endpoints. Results: Patients with or without prophylactic were similar in host factors and the majorities of characteristics regarding to tumor factors, HBV status, liver function and LMR. Notably, cycles of TACE were parallel between the groups. Ten (22.7%) patients receiving prophylactic entecavir reached virologic response. The patients receiving prophylactic entecavir presented significantly reduced virologic events (6.8% vs 54.4%, p
Hepatitis B virus;hepatocellular carcinoma;transcatheter arterial chemoembolization;hepatitis flare;
 Cited by
Changes of HBV DNA After Chemoembolization for Hepatocellular Carcinoma and the Efficacy of Antiviral Treatment, Digestive Diseases and Sciences, 2016, 61, 9, 2465  crossref(new windwow)
Current clinical evidence for nucleos(t)ide analogues in patients with HBV-related hepatocellular carcinoma, Expert Review of Gastroenterology & Hepatology, 2017, 11, 10, 925  crossref(new windwow)
Arzumanyan A, Reis HM, Feitelson MA (2013). Pathogenic mechanisms in HBV- and HCV-associated hepatocellular carcinoma. Nat Rev Cancer, 13, 123-35. crossref(new window)

Bruix J, Sherman M (2011). Management of hepatocellular carcinoma: an update. Hepatol, 53, 1020-2. crossref(new window)

Hongthanakorn C, Chotiyaputta W, Oberhelman K, et al (2011). Virological breakthrough and resistance in patients with chronic hepatitis B receiving nucleos (t)ide analogues in clinical practice. Hepatol, 53, 1854-63. crossref(new window)

Huang H, Li X, Zhu J, et al (2014). Entecavir vs lamivudine for prevention of hepatitis B virus reactivation among patients with untreated diffuse large B-cell lymphoma receiving R-CHOP chemotherapy: a randomized clinical trial. JAMA, 312, 2521-30. crossref(new window)

Jang JW, Choi JY, Bae SH, et al (2004). Transarterial chemolipiodolization can reactivate hepatitis B virus replication in patients with hepatocellular carcinoma. J Hepatol, 41, 427-35. crossref(new window)

Jang JW, Choi JY, Bae SH, et al (2006). A randomized controlled study of preemptive lamivudine in patients receiving transarterial chemo-lipiodolization. Hepatology, 43, 233-40. crossref(new window)

Jang JW, Kwon JH, You CR, et al (2011). Risk of HBV reactivation according to viral status and treatment intensity in patients with hepatocellular carcinoma. Antivir Ther, 16, 969-77. crossref(new window)

Kim IK, Kim BG, Kim W, et al (2012). Clinical prediction of failure of Lamivudine prophylaxis for hepatitis B virusinfected patients undergoing cytotoxic chemotherapy for malignancy. Antimicrob Agents Chemother, 56, 5511-9. crossref(new window)

Li X, Lin Q, Dong M, et al (2010). Prognostic analysis of acute exacerbations of hepatitis-B after chemotherapy in combination with rituximab in 19 patients with lymphoma. Leuk Lymphoma, 51, 1678-85. crossref(new window)

Li X, Xing YF, Lin Q, et al (2012). The treatment of severe hepatitis B virus reactivation after chemotherapy. Nat Rev Clin Oncol, 9, 350.

Li X, Zhong X, Chen ZH, et al (2014). Hepatitis B virus DNA negativity acts as a favorable prognostic factor in hepatocellular carcinoma patients. Asian Pac J Cancer Prev, 15, 9635-41. crossref(new window)

Liver EAftSot (2012). EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol, 57, 167-85. crossref(new window)

Lok AS, McMahon BJ (2007). Chronic hepatitis B. Hepatol, 45, 507-39. crossref(new window)

Lok AS, McMahon BJ (2009). Chronic hepatitis B: update 2009. Hepatol, 50, 661-2. crossref(new window)

McMahon BJ (2009). The natural history of chronic hepatitis B virus infection. Hepatol, 49, 45-55. crossref(new window)

Nagamatsu H, Itano S, Nagaoka S, et al (2004). Prophylactic lamivudine administration prevents exacerbation of liver damage in HBe antigen positive patients with hepatocellular carcinoma undergoing transhepatic arterial infusion chemotherapy. Am J Gastroenterol, 99, 2369-75. crossref(new window)

Park JW, Park KW, Cho SH, et al (2005). Risk of hepatitis B exacerbation is low after transcatheter arterial chemoembolization therapy for patients with HBV-related hepatocellular carcinoma: report of a prospective study. Am J Gastroenterol, 100, 2194-200. crossref(new window)

Peng JW, Lin GN, Xiao JJ, et al (2012). Hepatitis B virus reactivation in hepatocellular carcinoma patients undergoing transcatheter arterial chemoembolization therapy. Asia Pac J Clin Oncol, 8, 356-61. crossref(new window)

Torres HA, Davila M (2012). Reactivation of hepatitis B virus and hepatitis C virus in patients with cancer. Nat Rev Clin Oncol, 9, 156-66. crossref(new window)

Vizzini GB, Luca A, Marino IR (2003). Hepatitis B virus reactivation after a single session of transarterial chemoembolization in patients with hepatocellular carcinoma. Ann Intern Med, 138, 691-2.

Wu XY, Li X, Chen ZH, et al (2013). An optimized antiviral modification strategy for prevention of hepatitis B reactivation in patients undergoing prophylactic lamivudine and chemotherapy: a pilot study. Tumour Biol, 34, 909-18. crossref(new window)

Yeo W, Chan HL (2013). Hepatitis B virus reactivation associated with anti-neoplastic therapy. J Gastroenterol Hepatol, 28, 31-7. crossref(new window)

Zhong S, Yeo W, Schroder C, et al (2004). High hepatitis B virus (HBV) DNA viral load is an important risk factor for HBV reactivation in breast cancer patients undergoing cytotoxic chemotherapy. J Viral Hepat, 11, 55-9. crossref(new window)

Ziakas PD, Karsaliakos P, Mylonakis E (2009). Effect of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in lymphoma: a meta-analysis of published clinical trials and a decision tree addressing prolonged prophylaxis and maintenance. Haematologica, 94, 998-1005. crossref(new window)